Citius Oncology, Inc. CTOR
Citius Oncology, Inc. (Nasdaq: CTOR) is an oncology drug developer. Its lead program, LYMPHIR (denileukin diftitox-cdxl), is marketed for persistent or recurrent cutaneous T-cell lymphoma. Its next catalyst on record is Citius Oncology expects to report complete fiscal Q4 and full year 2026 results in December 2026 with Form 10-K filing. (December 2026).
Upcoming catalysts
- December 2026Citius Oncology expects to report complete fiscal Q4 and full year 2026 results in December 2026 with Form 10-K filing.
Citius Oncology expects to report complete fiscal fourth quarter and fiscal year 2026 results in December 2026 with the filing of its Annual Report on Form 10-K.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LYMPHIR | CTCL | protein/peptide | Approved |
Recent results and decisions
- Oct 10, 2026positive Citius Oncology presented positive health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma at the EORTC-CLTG 2026 Annual Meeting in Berlin.
In Study 302, patients who responded to denileukin diftitox-cxdl reported sustained quality of life improvements, and nearly a third of heavily pretreated patients with significant itch noted its decrease.
Filing - Mar 10, 2026positive Completed Phase 1 of LYMPHIR plus pembrolizumab showed 24% ORR and 48% clinical benefit rate in 21 evaluable patients, with no unexpected safety signals in 25 evaluable.
The trial explored efficacy and demonstrated a 24 % objective response rate (ORR) and a 48 % clinical benefit rate (CBR, defined as complete response, partial response and/or stable disease for six months or greater) among 21 evaluable patients.
Filing - Mar 4, 2026positive Investigator-initiated Phase 1 (n=14) of LYMPHIR before CAR-T showed 86% ORR (57% CR, 29% PR), 1-year PFS 77%, no dose-limiting toxicities.
Overall response rate (ORR) was 86% at one month, including 57% complete responses (CR) and 29% partial responses (PR);
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.